The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2025 | Advances in antibody-drug conjugates in oncogenic-addicted NSCLC
Giannis Mountzios, MD, Henry Dunant Hospital, Athens, Greece, discusses the efficacy and safety of antibody-drug conjugates (ADCs) in oncogenic-addicted non-small cell lung cancer (NSCLC). There is growing evidence of their potential in targeting oncogene-addicted tumors such as HER2- or MET-overexpressed tumors. ADCs can be categorized into biomarker-selected and biomarker-unselected, with the former requiring specific biomarkers for activation and the latter targeting widely expressed antigens. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ADCs are a new dynamic class of compounds. We call them antibody drug conjugates and my presentation will focus on the efficacy and safety data of ADCs, especially in the subgroup of patients with oncogenic non-small cell lung cancer. We have now a growing evidence that supports the notion that antibody drug conjugates may be particularly efficacious in patients with oncogene-addicted non-small cell lung cancer because of the presence of the target that enables the delivery of highly cytotoxic payload within the tumor microenvironment...
ADCs are a new dynamic class of compounds. We call them antibody drug conjugates and my presentation will focus on the efficacy and safety data of ADCs, especially in the subgroup of patients with oncogenic non-small cell lung cancer. We have now a growing evidence that supports the notion that antibody drug conjugates may be particularly efficacious in patients with oncogene-addicted non-small cell lung cancer because of the presence of the target that enables the delivery of highly cytotoxic payload within the tumor microenvironment. So in this sense we have two main categories of ADCs used in oncogene-addicted non-small cell lung cancer. The so-called biomarker-selected antibody drug conjugates and if we try to provide a definition these are the ADCs that require a specific biomarker to be expressed in a specific pattern for the ADC to be active. For example, ADCs against HER2 overexpression or HER2 mutation or MET overexpression. On the other hand, we have biomarker-unselected or biomarker-agnostic ADCs that by definition target a widely expressed antigenic epitope on the cancer cells, so they do not require a biomarker for their testing since this biomarker is almost universally expressed on cancer cells. This category mainly involves the anti-TROP2 antibodies and other kinds of ADCs like HER3-targeting antibodies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
